AHAtzin V. Hernández-Barbosa

Atzin V. Hernández-Barbosa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Atzin V. Hernández-Barbosa has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Azalia Juárez-Moya

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    2 shared publications
  • Benito A. Bautista-Martínez

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    2 shared publications
  • Emmanuel Jiménez-Aguayo

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    2 shared publications
  • Fabián I. Martínez-Becerril

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    2 shared publications
  • Israel Domínguez-Calderón

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    2 shared publications
  • Jorge Alfonso Martín-Trejo

    Servicio de Hematología, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México 06600, Mexico

    2 shared publications

Latest Publications

  • Open Access

    Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation

    by Lourdes Barbosa-Cortés, Sharon B. Morales-Montes, Michelle Maldonado-Alvarado, Jorge A. Martin-Trejo, Salvador Atilano-Miguel, Emmanuel Jiménez-Aguayo, Fabián I. Martínez-Becerril, Víctor M. Cortés-Beltrán, Atzin V. Hernández-Barbosa, Karina A. Solís-Labastida, et al.

    Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and during 6 weeks of post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω-3VDCa group (100 mg/kg/d LCPUFAs-ω3 + 4000 IU vitamin D + 1000 mg calcium) or the VDCa group (4000 IU vitamin D + 1000 mg calcium) for 6 weeks. Blood samples were collected to determine 25(OH)D, PTH, ICTP, and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 weeks, and 12 weeks after supplementation. The 25(OH)D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p < 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p = 0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω-3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p = 0.024). Conclusions: Combined omega-3 and 4000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.


  • Open Access

    Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation

    by Lourdes Barbosa-Cortés, Sharon B. Morales-Montes, Michelle Maldonado-Alvarado, Jorge A. Martin-Trejo, Salvador Atilano-Miguel, Emmanuel Jiménez-Aguayo, Fabián I. Martínez-Becerril, Víctor M. Cortés-Beltrán, Atzin V. Hernández-Barbosa, Karina A. Solís-Labastida, et al.

    Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and 6 weeks post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω3VDCa group (100 mg/kg/d LCPUFAs-ω3+4,000 IU vitamin D+1,000 mg calcium) or the VDCa group (4,000 IU vitamin D+1,000 mg calcium) for 6 weeks. Blood samples were collected to determine vitamin D (25(OH)D), PTH, ICTP and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 and 12 weeks after supplementation. The vitamin D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p< 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p=0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p=0.024). Conclusions: Combined omega-3 and 4,000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.